Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Drugs Inhibiting the KRAS Oncogene Suppress Growth of Pancreatic Tumors in Mouse Xenograft Model

By BiotechDaily International staff writers
Posted on 14 Jun 2013
Drugs that inhibit the activity of the enzyme GSK-3 alpha (glycogen synthase kinase 3 alpha) strongly suppress growth of human pancreatic tumor xenografts in mice as well as down regulate certain oncogenic NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells) target genes.

GSK-3 has since been identified as a kinase for over forty different proteins in a variety of different pathways. In mammals, GSK-3 is encoded by two known genes, GSK-3 alpha and GSK-3 beta. GSK-3 has recently been the subject of intense research because it has been implicated in a number of diseases, including type II diabetes, Alzheimer's disease, inflammation, cancer, and bipolar disorder.

Investigators at the University of North Carolina (Chapel Hill, USA) have found that in pancreatic cancer cells GSK-3 alpha is upregulated by mutant KRAS (Kirsten rat sarcoma viral oncogene). The KRAS gene performs an essential function in normal tissue signaling, and its mutation is an essential step in the development of many cancers. A single amino acid substitution is responsible for the activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas, and colorectal carcinoma.

In a paper published in the April 1, 2013, online edition of the journal Cancer Discovery, the investigators reported that GSK-3 alpha was required for promoting critical NF-kappaB signaling in pancreatic cancer cells. The transcription factors of the NF-kappaB family are upregulated in many human cancers. NF-kappaB has roles in all stages of carcinogenesis or cancer progression, including protection from cell death, increase of cell proliferation, cell motility and metastasis, tumor inflammation, and angiogenesis. In addition, tumor cells often acquire resistance to anticancer drugs by upregulating NF-kappaB signaling.

Pharmacologic inhibition of GSK-3 suppressed growth of human pancreatic tumor explants in mice, consistent with the loss of expression of oncogenic genes such as c-myc and TERT.

“GSK-3 promotes activity of a protein called NF-kappaB. Our lab has been studying NF-kappaB for a number of years and has published that this protein is important in KRAS signaling. But how KRAS activates NF-kappaB has not been well understood. We have found a link, ” said senior author Dr. Albert Baldwin, professor of biology at the University of North Carolina. “Our data suggest that GSK-3 alpha is really an onco-protein and that KRAS utilizes GSK-3 alpha to activate both NF-kappaB pathways, called canonical and noncanonical. This finding is important because GSK-3 alpha sits on top of the two pathways and inhibits them both, thus making it a viable therapeutic target. We are conducting further pharmacologic studies.”

Related Links:


University of North Carolina



Channels

Drug Discovery

view channel
Image: Wafers like the one shown here are used to create “organ-on-a-chip” devices to model human tissue (Photo courtesy of Dr. Anurag Mathur, University of California, Berkeley).

Human Heart-on-a-Chip Cultures May Replace Animal Models for Drug Development and Safety Screening

Human heart cells growing in an easily monitored silicon chip culture system may one day replace animal-based model systems for drug development and safety screening. Drug discovery and development... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.